Moderna stock surges 127% as cancer vaccine reshapes biotech outlook

Moderna shares have climbed roughly 127 percent in recent weeks and nearly sixfold over the past 12 months, after the biotech and Merck reported positive Phase 3 data for a personalized mRNA cancer vaccine in melanoma.

The Aug. 19 announcement from Moderna and Merck detailed positive top-line results from the INTerpath-001 trial, which tested Intismeran Autogene combined with Merck's Keytruda in patients with Stage IIB-IV melanoma, the companies said. The readout marks the first time an mRNA cancer vaccine has succeeded in a Phase 3 trial.

Shares initially surged as much as 175 percent on the news before settling around $140 to $145. Moderna now carries a market capitalization near $60 billion against estimated 2026 revenue of $2.1 billion, with forecast losses of $8.55 per share this year. The stock's 52-week range spans $22.28 to $176.66, a dramatic swing from the pandemic-era peak when the company was valued as a COVID-19 vaccine pure play.

The trial result suggests Moderna's mRNA platform can extend beyond infectious disease into oncology, a market with a far larger addressable patient population. But with commercialization years away and the current valuation already pricing in substantial future potential, the question is whether the rally has run ahead of the science.

Intismeran Autogene is a personalized neoantigen therapy that uses mRNA to encode tumor-specific mutations, training the immune system to recognize and attack cancer cells. The approach differs from standard checkpoint inhibitor therapy, which removes brakes on the immune system rather than actively directing it toward tumor antigens. The combination with Keytruda is designed to both activate and unleash the immune response simultaneously.

The partnership structure matters for both companies. Merck supplies Keytruda, its blockbuster PD-1 inhibitor that generated roughly $30 billion in annual sales, while Moderna contributes its mRNA manufacturing platform. A successful combination could extend Keytruda's franchise and give Moderna a foothold in oncology that its COVID-19 vaccine franchise never provided. The collaboration also positions Moderna against BioNTech, which is pursuing its own mRNA cancer vaccine programs with partner Genentech.

$60B valuation vs. years to commercialization

The market's response reflects genuine scientific progress, but the numbers warrant scrutiny. Moderna's $60 billion market cap against $2.1 billion in projected 2026 revenue implies investors are paying for oncology upside that remains several years from commercialization. The company's forecast losses of $8.55 per share this year show the cash burn inherent in running multiple late-stage trials.

Short sellers may have contributed to the move. The initial 175 percent spike followed by a pullback to current levels around $138 suggests some of the rally was driven by forced covering rather than fundamental repositioning. A further cooldown could occur as the market recalibrates expectations around regulatory timelines and eventual pricing.

The path forward involves regulatory submissions, manufacturing scale-up, and expansion into additional cancer types. Moderna and Merck will need to demonstrate that the melanoma results translate across other indications where the personalized vaccine approach could apply. For investors, the key question is whether the current valuation already reflects these milestones or whether the market is pricing in a best-case scenario.

Moderna shares, trading around $138, have already priced in substantial oncology upside. Merck, at roughly $148, offers more diversified exposure to the same partnership through its broader oncology franchise. Investors considering Moderna may want to wait for a pullback that brings valuation closer to the company's near-term fundamentals, given that the oncology revenue contribution remains years away.

This article is for informational purposes only and does not constitute investment advice.